Addenda Capital Inc. Has $7.06 Million Stock Position in Medtronic PLC $MDT

Addenda Capital Inc. lowered its holdings in shares of Medtronic PLC (NYSE:MDT) by 9.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 73,000 shares of the medical technology company’s stock after selling 7,977 shares during the period. Addenda Capital Inc.’s holdings in Medtronic were worth $7,064,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. State Street Corp lifted its holdings in shares of Medtronic by 1.0% in the third quarter. State Street Corp now owns 60,460,537 shares of the medical technology company’s stock valued at $5,800,550,000 after purchasing an additional 625,992 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Medtronic by 0.9% during the third quarter. Bank of New York Mellon Corp now owns 21,468,260 shares of the medical technology company’s stock worth $2,044,637,000 after acquiring an additional 192,410 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in Medtronic by 0.5% during the third quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company’s stock worth $2,008,278,000 after acquiring an additional 98,220 shares during the period. Raymond James Financial Inc. lifted its holdings in Medtronic by 3.0% during the third quarter. Raymond James Financial Inc. now owns 11,203,865 shares of the medical technology company’s stock worth $1,067,055,000 after acquiring an additional 327,899 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in Medtronic by 35.3% during the third quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company’s stock worth $970,456,000 after acquiring an additional 2,658,981 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: FDA clearance expands robotic/surgical addressable market — Medtronic received U.S. FDA clearance for its AI-enabled Stealth AXiS system for cranial and ENT procedures, extending the platform beyond spine and broadening opportunities in computer-assisted and robotic surgery. This is a clear product-side growth catalyst for surgical robotics and navigation adoption. Assessing Medtronic Valuation After Stealth AXiS FDA Clearance
• Positive Sentiment: Market tailwinds in core device markets — industry reports highlight multi-year growth in anesthesia/respiratory and lung-cancer surgery markets, with Medtronic named among leading vendors; these secular trends support steady revenue opportunities for MDT’s device franchises. Anesthesia & Respiratory Market Report Lung Cancer Surgery Market
• Neutral Sentiment: Investor note and price action coverage — market write-ups (e.g., Zacks) point to MDT’s intraday move and recent momentum; useful for short-term sentiment tracking but largely descriptive. Zacks: What Investors Need to Know
• Neutral Sentiment: Mixed analyst adjustments — several firms trimmed price targets (Evercore, Citi, others) but mostly kept positive/neutral ratings (buy/outperform/hold). That leaves medium-term upside in some models but increases short-term uncertainty. Evercore PT Adjustment Citi PT Adjustment
• Negative Sentiment: Stifel trims target citing MiniMed IPO impacts — Stifel cut its price target to $95 and flagged transaction-related effects from the recent MiniMed IPO as a reason for lowering near-term expectations; that raises near-term analyst-model risk and may weigh on sentiment. Stifel Cuts MDT Target to $95
• Negative Sentiment: Competitive pressure in cardiac rhythm devices — Johnson & Johnson launched an enhanced pulsed-field ablation device in Europe, signaling faster product rollouts from competitors in electrophysiology that could pressure share gains in select cardiac franchises. J&J launches enhanced PFA device

Wall Street Analysts Forecast Growth

A number of analysts recently commented on MDT shares. Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Citigroup dropped their price target on Medtronic from $117.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday. Robert W. Baird lowered their target price on Medtronic from $103.00 to $100.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 18th. Mizuho upgraded Medtronic to a “strong-buy” rating in a research note on Wednesday, February 18th. Finally, Leerink Partners restated an “outperform” rating and issued a $119.00 target price on shares of Medtronic in a research note on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $109.10.

Medtronic Price Performance

Medtronic stock opened at $88.65 on Thursday. The business has a 50-day simple moving average of $93.66 and a 200 day simple moving average of $96.07. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The stock has a market cap of $113.81 billion, a price-to-earnings ratio of 24.69, a PEG ratio of 2.24 and a beta of 0.75.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. During the same period in the prior year, the business earned $1.38 EPS. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic’s payout ratio is 79.11%.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the transaction, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.26% of the stock is owned by insiders.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).